Odansetron for Treatment of Acute Kidney Injury

In the United States, more that 60% of patients admitted to the ICU will suffer acute kidney injury (AKI), also called acute renal or acute kidney failure. Patients with AKI have longer ICU and hospitalization stays and have a significantly increased risk of mortality within one year after ICU admission. AKI can also lead to the development of chronic kidney disease (CKD) or necessitate kidney transplant surgery. The pathology of AKI is still not clear and no effective drug has been identified.

Description

Using electronic medical records (EMR) from more than twenty thousand AKI patients in ICU stays, researchers identified a novel indication for odansetron, an antiemetic drug used to prevent nausea caused by chemotherapy, in preventing death of patients with AKI. The molecular mechanism of odansetron suggests that it can down-regulate AKI-related genes. Odansetron’s beneficial effects on recovery from acute injury have never been reported before.

Applications

· Treating acute kidney injury

Advantages

· No other drugs with beneficial effects on acute kidney injury prognosis have been identified

Invention Readiness

In vivo and clinical data

IP Status

https://patents.google.com/patent/US20240009173A1

Related Publication(s)

Gray, M., Priyanka, P., Kane-Gill, S., Wang, L., & Kellum, J. A. (2022). Kidney and Mortality Outcomes Associated with Ondansetron in Critically Ill Patients. Journal of Intensive Care Medicine, 37(10), 1403–1410. https://doi.org/10.1177/08850666211073582